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Europe.
Results: Out of 11195 consecutive PCI pts 6611 (59%) underwent PCI for ACS. In this
subgroup 1564/6611 (24%) were diabetics. 
Independent determinants for the use of GP IIb/IIIa during PCI for ACS were male gen-
der (OR 1.30, 1.16-1.45) and cardiogenic shock (OR 1.69, 1.24-2.30). Determinants 
against GP IIb/IIIa were age >70 years (OR 0.64, 0.58-0.71), prior MI (OR 0.68, 0.68-
0.77) and prior CABG (OR 0.69, 0.58-0.82). Known diabetes did not influence the deci-
sion for the use of GP IIb/IIIa (OR 0.96, 0.86-1.07).
Conclusion: Less than half of diabetic pts undergoing PCI for ACS in Europe received 
GP IIb/IIIa during PCI. Despite the evidence of an improved outcome in especially diabet-
ics, the frequency of GP IIb/IIIa use during PCI for ACS was not different from that in non-
diabetics in clinical practice. In a multivariate analysis diabetes mellitus was no determi-
nant for the use of GP IIb/IIIa for ACS in Europe.
ORAL CONTRIBUTIONS
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Monday, March 08, 2004, 4:00 p.m.-5:30 p.m.
Morial Convention Center, Room 257
4:15 p.m.
829-2 Frequency and Evolution of Microvascular Obstruction 
Early After Interventional Therapy of Acute Myocardial 
Infarction
Gilbert L. Raff, Ralph E. Gentry, James A. Goldstein, William Beaumont Hospital, Royal 
Oak, MI
Background
Microvascular obstruction (MO), a predictor of adverse clinical outcomes after acute
myocardial infarction (AMI), has been reported in 25-65% of patients examined 4-10 days
after AMI. Contrast-enhanced cine magnetic resonance imaging can sensitively detect
MO. The present study was designed to determine the frequency of MO within 24 hours
after primary percutaneous intervention therapy (PCI) of AMI, and its evolution over time.
Methods
We imaged 43 patients within 24 hours after PCI, and did repeat CEC after one week in
25 and after three months in 43. All patients had TIMI 3 flow on angiography. Approxi-
mately one minute after 0.20mmol/kg of I.V. gadolinium-DTPA contrast, nine 8mm short
axis and two long-axis images were obtained, using an EKG-gated, segmented k-space
true-FISP cine pulse sequence. At approximately 10 minutes, after scanning inversion
time to optimally null myocardium, an inversion-recovery turbo-FLASH delayed enhance-
ment study was done in the same slices. MO defects were identified as discrete regions
of endocardially-based hypoenhancement. These were measured by planimetry as a
percent of total infarct area, and classified as mild (1-10%), moderate (11-20) and severe
(>20%). Analysis was done by two blinded observers, with planimetered areas averaged
between the two.
Results
Studies performed within 24 hours of infarct intervention documented MO in 37/43 (86%)
patients. Among patients with large defects, mean size was 32.1% of total infarct area.
Later follow-up studies (performed 7 +/-5 days post-AMI) showed decrease in average
MO size to 18.2% (P=0.002). At three months, MO was visible in only 4/43 (9%) of
patients.
Conclusions
Microvascular obstruction is more common than previously reported early after success-
ful PCI therapy of AMI, and its presence decreases with time. Rapid diagnosis of MO by
contrast-enhanced cine MRI may be of value in the development of novel therapies for
no-reflow.
4:30 p.m.
829-3 Early Results From the Japanese Asparagus Trial
Toshiya Muramatsu, S. Suwa, S. Koyama, N. Fujita, M. Saito, H. Kamiya, A. Oida, T. 
Tsuchiya, Y. Horit, Kawasaki Social Insurance Hospital, Kawasaki, Japan
Background:
Distal embolization may result in slow flow, no re-flow and reduced myocardial perfusion,
increasing the risk of non-Q-wave MI & death. Embolic Protection devices may protect
the micro-vasculature from thrombo-emboli improving short and long-term clinical out-
comes. We designed the ASPARAGUS Trial, ASPirAtion of LibeRated Debris in Acute MI
with GUardwire System, a multicenter , Prospective, Randomized trial using the Percu-
Surge GuardWire® System in the treatment of acute MI.a To assess the safety and effec-
tiveness of adjunctive Embolic Protection in patients with an acute MI. 
Methods:
ASPARAGUS is 26 institutes, prospective, randomized trial enrolling up to 300 random-
ized patients. Patients experiencing AMI consented within 12 hours of symptom onset
who are likely to be treated with Stenting and who meet entry criteria are eligible for ran-
domization. To compare to intervention with/without protection will result in faster and
more complete ST-segment resolution, smaller infarct size, and improved myocardial per-
fusion.
Results:
336 patients were enrolled then 230 patient were observed as an early clinical result.
Including 80 Angiographic data (post procedure TIMI flow, Myocardial blush, Corrected
TIMI frame count ) and 180 ECG data. (the magnitude of ST segment resolution at 90
and 180 mins after procedure) were analyzed by core- laboratory.
Procedural and hospital outcomes are summarized in the Table.
-------------------------------------------------------------------------------------------------
Control GuardWire use
Device success 99 .2% (137/138)
Distal Embolization 4.4% (5/114) 2.4% (3/125)
Death 7.9% (9/114) 5% (6/125)
Non–Q-wave MI 0.9% (1/114) 0.8% (1/125)
-------------------------------------------------------------------------------------------------
Conclusion:
This early results from an ongoing multicenter trial suggests that the GuardWire is safe
and effective in reducing athero-embolism during percutaneous coronary intervention of
acute MI. Completed angiographic and clinical follow-up will be presented.
4:45 p.m.
829-4 Dose Thrombus Aspiration With Distal Protection Using 
PercuSurgeTM Before Stenting for Acute Myocardial 
Infarction Reduce No-Reflow Phenomenon?
Yoshiaki Ito, Toshiya Muramatsu, Reiko Tsukahara, Keisuke Hirano, Shigeru Nishimura, 
Kawasaki Social Insurance Hospital, Kawasaki, Japan
Background: No-reflow phenomenon is a problematic complication in reperfusion ther-
apy for AMI. Main cause of the no-reflow is a embolism of the thrombus or plaque compo-
nents.We examined the thrombus aspiration with distal protection using PercuSurgeTM
during percutaneous coronary intervention for AMI reduce the risk of no-reflow.
Subjects and Methods: Serial 522 patients with AMI onset from 24 hours were exam-
ined. These patients spirit into the three groups;stenting without aspiration groups(S-
group,n=305),stenting with aspiration only using RescueTM groups(R-
group.n=140),stenting with aspiration with distal protection using PercuSurgeTM
groups(P-group,n=77). TIMI III flow grade after PCI, TIMI frame count(TFC) after PCI,
frequency of no-reflow, cahanges of left ventricular ejection fraction(LVEF) in immediately
after PCI and pre discharge(average 11 days) and major adverse cardiac events(MACE)
durling hospitalization were evaluated.
Results: There were no differences in terms of patient age, risk factors, reperfusion time
from onset, or target vessel diameter or size of stent used. TIMI III flow grade after PCI
were significant higher in P-group. TFC after PCI were significant lower in P-
group(18.3±8.4,22.4±13.4,26.4±18.5,p<0.05). Frequency of no-reflow were significant
lower in P-group(1.3%,10%,14.1%respectively).LVEF immediately after PCI were no sig-
nificant different in 3groups,but LVEF at pre discharge were significantly higher in P-
group(62±9,56±13,54±14% respectively). MACE were no significant difference between
groups but pump failure trended to lower in P-group.Conclusion: Our results suggest
that using the PercuSurge as a reperfusion therapy for AMI reduce no-reflow phenome-
non and maintain of the LVEF during acute phase hospitalization.
5:00 p.m.
829-5 Primary Angioplasty in Acute Myocardial Infarction With 
Distal Protection of the Microcirculation: Principal 
Results From the Prospective, Randomized EMERALD 
Trial
Gregg W. Stone, John Webb, David A. Cox, Bruce R. Brodie, Mansoor Qureshi, Daniel 
Dulas, Anna Kalynych, Mark Turco, Heinz P. Schultheiss, Barry Rutherford, Mitch 
Kruckoff, Raymond Gibbons, Alexandra J. Lansky, Ramona Pop, Roxana Mehran, 
Denise Jones, Cardiovascular Research Foundation, New York, NY, Lenox Hill Heart and 
Vascular Institute, New York, NY
Background. Distal embolization during primary percutaneous coronary intervention
(PCI) for AMI is common, and may result in diminished myocardial perfusion, incomplete
ST segment resolution (STR), impaired myocardial recovery and increased mortality.
Diabetics
n = 1564
Non-Diabetics
n = 5047
p-value
Age [years] 64 69 <0.001
Male Gender 65.4 % 77.7 % <0.001
Prior MI 26.5 % 21.2 % <0.001
Prior Stroke 5.9 % 3.2 % <0.001
Renal Failure 5.6 % 2.6 % <0.001
Cardiogenic Shock 3.8 % 2.2 % <0.001
Heart Failure 4.0 % 2.3 % <0.001
3-Vessel-Disease 28.3 % 20.8 % <0.001
GP IIb/IIIa receptor blocker 45.9 % 47.0% ns
Reason for GP IIb/IIIa
ACS 61.2 % 65.6 % <0.001
Pt considered high risk 16.5 % 11.2 % <0.001
30-Day-Mortality 3.7 % 2.3 % <0.001
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Single center registries have shown that distal protection with the Medtronic (Percu-
Surge) GuardWire balloon occlusion and aspiration system is capable of retrieving
embolic particulate debris in a large percentage of patients undergoing primary PCI.
Whether this translates into improved reperfusion success and enhanced outcomes has
not been determined.
Methods. In the EMERALD trial, 500 pts within 6 hrs onset of chest pain with >2 mm ST
elevation in 2 or more contiguous leads, or LBBB, undergoing primary or rescue PCI are
being prospectively randomized at 40 sites to angioplasty with vs. without distal protec-
tion with the 0.028” GuardWire Plus system. The primary endpoints include STR 30 mins
post procedure (measured by 24 hour continuous ECG monitoring) and infarct size
assessed by tc-99m-sestamibi imaging at day 5-14. The study is powered to show an
improvement in complete STR from 50% with control to 65% with distal protection (a 30%
relative increase), and a reduction in mean infarct size from 13.1% of the left ventricle to
8.8%. (a 33% relative decrease). Secondary efficacy endpoints include achievement of
normal (grade 3) myocardial blush by core lab analysis, and the composite clinical rate of
death, new onset sustained hypotension or severe heart failure, and readmission for left
ventricular failure within 30 days.
Results. To date, more than 415 pts have been randomized; enrollment will be complete
by November 2003.
Conclusions. A large-scale, prospective, randomized multicenter trial has been per-
formed to: 1) Examine whether prevention of distal embolization in patients undergoing
primary PCI for AMI improves indices of myocardial reperfusion and resolution of ongo-
ing injury, reduces infarct size and improves clinical outcomes, and 2) Evaluate the
safety, feasibility and efficacy of the GuardWire balloon occlusion and aspiration system
for this application. The principal results will be reported for the first time in March 2004.
5:15 p.m.
829-6 A Randomized Trial Comparing Rheolytic 
Thrombectomy Before Infarct Artery Stenting With 
Stenting Alone in Patients Undergoing Percutaneous 
Coronary Intervention for Acute Myocardial Infarction
Guido Parodi, Renato Valenti, Angela Migliorini, Gentian Memisha, Emilio V. Dovellini, 
Giampaolo Cerisano, David Antoniucci, Careggi Hospital, Florence, Italy
Background Macro and microembolization of atherothrombotic debris during percutane-
ous coronary intervention (PCI) for acute myocardial infarction (AMI) are frequent and
may result in the obstruction of the microvessel coronary network and decrease in effec-
tiveness of mechanical reperfusion.
Methods This randomized trial compared rheolytic thrombectomy before direct infarct
artery stenting with direct infarct artery stenting alone in 100 patients with a first AMI. The
effectiveness of reperfusion was assessed by analysis of ST-segment resolution at 30
min after infarct related artery (IRA) recanalization, by corrected TIMI frame count
(cTFC), and by 1-month 99mTc-Sestamibi scintigraphy infarct size. The primary end point
of the study was early ST-segment resolution, and the secondary end points were cTFC,
infarct size, and 1-month clinical outcome.
Results There were no significant differences between randomized groups in baseline
characteristics. Most patients had abciximab treatment (98%) and IRA stenting (98%).
Among direct stenting alone group the cross over to thrombectomy was 8% and was due
to residual angiographic evidence of massive thrombosis after stenting. Thrombectomy
catheter could successfully cross the lesion before stenting in 96% of patients. The pri-
mary end point rate was 90% in the thrombectomy group, and 72% in the direct stenting
alone group (p=0.022). At multivariate logistic regression analysis, randomization to
thrombectomy was related to the primary end point (OR: 3.56; 95% CI: 1.11-11.42; p =
0.032). cTFC was lower in the thrombectomy group (18.2 ± 7.7 vs 22.5 ± 11.0; p=0.032),
and infarct size smaller in the thrombectomy group (13.0 ± 11.6% vs 21.2 ± 18.0%;
p=0.010). At 1 month, there were no major cardiac adverse events in both groups.
Conclusions Rheolytic thrombectomy before routine direct IRA stenting is highly feasi-
ble and provides a more effective myocardial reperfusion in patients undergoing PCI for
AMI.
ORAL CONTRIBUTIONS
833 
Adjunctive Medical Therapy for Acute 
Myocardial Infarction
Tuesday, March 09, 2004, 8:30 a.m.-10:00 a.m.
Morial Convention Center, Room 260
8:30 a.m.
833-1 Use of Angiotensin-Converting Enzyme Inhibitors After 
Acute Myocardial Infarction Is Associated With a 
Striking Reduction in 30-Day and One-Year Mortality: 
Insights From GUSTO V
Deepak P. Vivekananthan, A. Michael Lincoff, Hitinder S. Gurm, Danielle Brennan, Eric J. 
Topol, Cleveland Clinic Foundation, Cleveland, OH
Background:The use of angiotensin converting enzyme inhibitors (ACE-I) has been
shown to provide a reduction in mortality in high-risk patients after myocardial infarction
(MI). However, the benefit of routine administration of ACE-I in lower risk MI patients after
fibrinolytic therapy has not been well studied.
Methods: We used data from the GUSTO V trial to compare all-cause mortality among
patients who received ACE-I (n=9352) between 24 hours of trial enrollment and hospital
discharge and those who did not receive ACE inhibitors (n=6867) within this time frame.
Use of ACE-I was left to discretion of the treating physician. We performed a propensity
analysis to fully adjust for selection bias in the prescription of ACE-I.
Results: Patients prescribed ACE-I tended to be older and had a higher percentage of
diabetes, anterior wall MI, and history of hypertension. The incidence of prior congestive
heart failure (CHF) was low in both groups (<4%). Over 96% of patients in both groups
were Killip 1 or 2. There were 587 deaths (3.5%) at 30 days and 1021 deaths (6.3%) at
one year. Despite a higher risk factor profile, patients prescribed ACE-I had a lower mor-
tality at 30-days (2.8% vs. 4.8%, p<0.001) and one-year (5.7% vs. 7.1%, p<0.001). After
adjusting for the propensity to receive ACE-I and known confounders, the prescription of
ACE-I was associated with a significant decrease in 30-day mortality (OR 0.43; 95% CI
0.34 - 0.53, p<0.001).
Conclusions: In-hospital initiation of ACE-I after fibrinolytic therapy for acute MI, even in
lower-risk patients, is associated with a dramatic reduction in short-term and long-term
mortality. This study adds to the growing evidence supporting the routine use of ACE-I in
all patients with acute myocardial infarction.
8:45 a.m.
833-2 Long-Term Effects of Statin Therapy in Patients With 
Acute ST-Elevation Myocardial Infarction and Moderate 
or Severe Left Ventricular Dysfunction: Reduction of 
Mortality but Not of Nonfatal Major Adverse Coronary 
and Cerebrovascular Events
Thomas Kleemann, Rudolf Schiele, Anselm Gitt, Claus Jünger, Harm Wienbergen, 
Jochen Senges, Bernhard Rauch, The MITRA PLUS Study Group, Herzzentrum 
Ludwigshafen, Ludwigshafen, Germany
Background: Different randomized clinical trials have shown that statins reduce mortal-
ity and major adverse coronary and cerebrovascular events (MACCE) in the setting of
acute myocardial infarction. These trials had focused mainly on patients (P) with pre-
served or slightly reduced left ventricular function. Aim of the study was to evaluate the
prognostic impact of statin therapy in P with ST elevation acute myocardial infarction
(STEMI) and moderate or severe left ventricular dysfunction (LVD). Patients and meth-
ods: 1402 consecutive P with acute STEMI and a LVD (ejection fraction < 40%) of the
prospective multicenter registry Maximal Individual Therapy of Acute Myocardial Infarc-
tion PLUS (MITRA PLUS) were analyzed. 1034 (74%) P received statin therapy.
Results: After a median follow-up time of 399 [353-574] days, the all-cause mortality of P
not receiving statin therapy was more than twice as high as in P receiving statin therapy
(26.9% versus 12.6%, p< 0.0001).
Conclusion: 1. In P with acute STEMI and moderate or severe LVD statin therapy was
associated with a 36% reduction of long-term mortality. 2. In contrast to previous clinical
trials performed in P with preserved or slightly decreased LVD, statins did not reduce
nonfatal MACCE in P with moderate or severe LVD.
9:00 a.m.
833-3 Statin Therapy and Mortality in Patients With Acute 
Myocardial Infarction Treated With Primary Angioplasty
Giuseppe De Luca, Harry Suryapranata, Jan Paul Ottervanger, Arnoud JW van't Hof, Jan 
CA Hoorntje, AT Marcel Gosselink, Jan-Henk E Dambrink, Felix Zijlstra, Menko-Jan de 
Boer, De Weezenlanden Hospital, Zwolle, The Netherlands
Background. Previous studies have shown that statin therapy can reduce long-term
mortality in patients with significant risk factors for coronary artery disease or stable
angina. However the benefits of statins in patients with ST-segment elevation myocardial
infarction (STEMI) have yet to be extablished. Thus the aim of the current study was to
determine whether statin therapy is associated with a reduction in mortality in patients
with STEMI treated with primary angioplasty.
Methods. A total of 1513 consecutive in-hospital survivors treated with primary angio-
plasty for STEMI between April 1997 and October 2001 represent the population of the
current study. All clinical, angiographic and 1-year follow-up data were prospectively col-
lected.
Results. A total of 893 (59%) patients were on statins at discharge. At 1 year follow-up
statins therapy was associated with a significantly lower mortality (1.2% vs 7.1%, RR
[95% CI] = 0.16 [0.09-0.32], p < 0.0001). In almost all groups of patients identified by the
propensity score analysis, statin therapy was associated with a significant reduction in
mortality. Furthermore, statin therapy was an independent predictor of mortality at multi-
variate analysis (adjusted RR [95% CI] = 0.24 [0.12-0.47], p < 0.0001).
Conclusions: Statin therapy at discharge is associated with a significant reduction in 1-
Multiple logistic regression of outcome: statin versus no statin in acute STEMI 
and LVD
Odds ratio 95% Confidence interval
Long-term mortality 0.64 0.45 - 0.90
Nonfatal reinfarction 1.15 0.52 - 2.55
Nonfatal stroke 0.53 0.19 - 1.44
CABG 1.07 0.62 - 1.83
PTCA 0.88 0.50 - 1.53
